Post-Conference Perspectives: 2022 San Antonio Breast Cancer Symposium Highlights

Charles E. Geyer, MD and Ian E. Krop, MD, PhD review current trends in the breast cancer treatment landscape, discuss new data presented at the 2022 San Antonio Breast Cancer Symposium as well as other major findings presented over the course of the year.

EP. 1: The Evolution of the Breast Cancer Treatment Landscape

January 11th 2023

Charles E. Geyer, MD and Ian E. Krop, MD, PhD provide an overview of the current breast cancer treatment landscape, with a focus on the management of patients with ER+/HER2- metastatic breast cancer.

EP. 2: Updates in the Treatment of Early-stage HR+ Breast Cancer

January 11th 2023

Two breast cancer experts review updates from the SOFT and TAILORx trials and discuss racial disparities in breast cancer treatment and clinical trials.

EP. 3: Novel Agents in the Adjuvant Setting: PARP Inhibitors

January 18th 2023

Dr Geyer and Dr Krop explore data from the OlympiA phase III trial of adjuvant olaparib in patients with variants in BRCA1/2.

EP. 4: Clinical Implications of SERENA-2 Trial Data

January 18th 2023

Conversation centered around the clinical implications of recently presented data from the randomized, multi-dose phase II SERENA-2 trial.

EP. 5: Recent Updates for the Advanced HR+ Breast Cancer Setting

January 25th 2023

Charles E. Geyer, MD and Ian E. Krop, MD, PhD touch on recent advances in the metastatic HR+ breast cancer setting and evaluate PROTAC estrogen receptor (ER) degraders compared with other ER modulators.

EP. 6: Key Takeaways from Clinical Trials of Trastuzumab Deruxtecan in Different Populations

January 25th 2023

Dr Krop leads a discussion of results from the DESTINY-Breast02 and DESTINY-Breast03 studies concerning the use of trastuzumab deruxtecan in patients with metastatic breast cancer.

EP. 7: Unmet Needs for Patients with HER2+ Breast Cancer with Brain Metastases

February 1st 2023

Breast cancer experts exchange thoughts on the treatment of HER2+ breast cancer with CNS involvement, particularly the use of trastuzumab deruxtecan in this subset of patients.

EP. 8: The Emerging State of HER2-low Breast Cancer

February 1st 2023

Dr Geyer and Dr Krop discuss key data and the evolving standard of care for patients with HER2-low breast cancer.

EP. 9: Trastuzumab Deruxtecan in the Neoadjuvant Setting

February 8th 2023

Closing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.